The first vaccine for Parkinson's may be available
Researchers have started the first Phase I clinical trial for the development of a Parkinson's vaccine (PD01A). This is the first time a vaccine has the potential to treat the cause of Parkinson's. The study will test this vaccine on up to 32 patients with Parkinson's disease.
There are medications that influence the symptoms of Parkinson's, but none of them can modify the course of the disease, that is why PD01A the first potential vaccine to treat the cause of this condition. The vaccine targets a protein called alpha-Synuclein which plays an important role in the onset and progression of Parkinson's. The aim of the vaccine is to instruct the immune system to produce antibodies directed against alpha-syn.
Parkinson's is caused by deposits of pathological forms of alpha-syn in the brain. Reducing the alpha-syns in the brain has a beneficial effect on the progress of the disease. PD01A shall accomplish that upon the induction of antibodies that are targeting alpha-syn, to neutralize its toxic impact.